Prognostic and predictive value of plasma D-dimer in advanced non-small cell lung cancer patients undergoing first-line chemotherapy

Clinical and Translational Oncology

Volumn 17, Issue 1, 2015, Pages 57-64

  Ge, L P ^a   Li, J ^a   Bao, Q L ^a   Chen, P ^a   Jiang, Q ^a   Zhu, L R ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Chemotherapy; D dimer; Non small cell lung cancer; Prediction; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CROSS LINKING REAGENT; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; TUMOR MARKER;

ADULT; AGED; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CROSS-LINKING REAGENTS; DISEASE-FREE SURVIVAL; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84940285634     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1198-2     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
2. Jett JR, Schild SE, Keith RL, Kesler KA. Treatment of non-small cell lung cancer, stage IIIB ACCP evidence-based clinical practice guidelines (2nd edn). Chest. 2007;132(suppl):266s–76s.
3. Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, et al. Treatment of non-small cell lung cancer, stage IV ACCP evidence-based clinical practice guidelines (2nd edn). Chest. 2007;132(suppl):277s–89s.
4. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kapalan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and treatment of cancer, National Cancer Institute of the United states, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
5. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer. 2006;107:2842–9.
6. Ishiguro F, Fukui T, Mori S, Katayama T, Sakakura N, Hatooka S, et al. Serum carcinoembryonic antigen levels as a surrogate marker for the evaluation of lung response to chemotherapy in nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg. 2010;16:242–7.
7. Indovina P, Marcelli E, Maranta P, Tarro G. Lung Cancer proteomics: recent advances in biomarker discovery. Int J Proteomics 2011;2011:1–7. doi:10.1155/2011/726869.
8. Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009;27:4821–6.
9. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulabe state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4:465–73.
10. Falanga A, Panove-Noeva M, Russo L. Procoagulant mechanism in tumor-cells. Best Pract Res Clin Haematol. 2009;22:49–60.
11. Kvolik S, Jukic M, Matijevic M, Marjanovic K, Glavas-Obrovac L. An Overview of coagulation disorders in cancer patients. Surg Oncol. 2010;19:33–46.
12. Lippi G, Franchini M, Targher G, Favaloro EJ. Help me, doctor! My D-dimer is raised. Ann Med. 2008;40:594–605.
13. Batschauer APB, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LMS, Fernandes AP, et al. D-Dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. 2010;21:1267–72.
14. Blackwell K, Haroon Z, Broadwater G, Berry O, Harris L, Iglehart JD, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000;18:600–8.
15. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002;86:389–95.
16. Kwon H-C, Oh SY, Lee S, Kim S-H, Han JY, Koh RY, et al. Plasma levels of prothrombin fragment F1 + 2, D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. Jpn J Clin Oncol. 2008;38:2–7.
17. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer levels is associated with advanced tumor stage and shorter survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001;31:388–94.
18. Blackwell K, Hurcvitz H, Lieberm G, Novotny W, Snyder S, Dewhirst M, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer. 2004;101:77–82.
19. Gadducci A, Baicchi U, Marrai R, Facchini V, del Bravo B, Fosella PV, et al. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status. Gynecol Oncol. 1993;49:354–8.
20. Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, et al. Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer. Am J Clin Pathol. 2010;134:964–9.
21. Hong SK, Ko DW, Park J, Kim IS, Doo SH, Yoon CY, et al. Alteration of antithrombin III and D-dimer levels in clinically localized prostate cancer. Korean J Urol. 2010;51:25–9.
22. Tomimaru Y, Yano M, Takachi K, Kishi K, Miyashiro I, Ohue M, et al. Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg. 2006;202:139–45.
23. Diao D, Zhu K, Wang Z, Cheng Y, Li K, Pei L, et al. Prognostic value of the D-dimer test in oesophageal cancer during the perioperative period. J Surg Oncol. 2013;108:34–41.
24. Antoniou D, Pavlakou G, Stathopoulos GP, Karydis I, Chondrou E, Papageorgiou C, et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer. 2006;53:205–10.
25. Altiay G, Ciftci A, Demir M, Kocak Z, Sut N, Tabakoglue, et al. High Plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol. 2007;19:494–8.
26. Zhang PP, Sun JW, Wang XY, Liu XM, Li K. Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism. Eur J Surg Oncol. 2013;39:951–6.
27. Baccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma clinical and prognostic significance. Cancer. 2003;97:3044–52.
28. Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation test in lung cancer. Eur Respir J. 2001;17:667–73.